These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23337457)

  • 1. [The irritable bowel syndrome, should not be considered a functional disorder?].
    Sebastián Domingo JJ
    Med Clin (Barc); 2013 May; 140(9):403-5. PubMed ID: 23337457
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic potential of ketotifen in irritable bowel syndrome (IBS) may involve changes in mast cells at sites beyond the rectum.
    O'Sullivan M
    Gut; 2011 Mar; 60(3):423; author rpely 423. PubMed ID: 20921205
    [No Abstract]   [Full Text] [Related]  

  • 3. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome.
    Klooker TK; Braak B; Koopman KE; Welting O; Wouters MM; van der Heide S; Schemann M; Bischoff SC; van den Wijngaard RM; Boeckxstaens GE
    Gut; 2010 Sep; 59(9):1213-21. PubMed ID: 20650926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship?
    Braak B; Klooker TK; Wouters MM; Welting O; van der Loos CM; Stanisor OI; van Diest S; van den Wijngaard RM; Boeckxstaens GE
    Am J Gastroenterol; 2012 May; 107(5):715-26. PubMed ID: 22488080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4h-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat.
    Serna H; Porras M; Vergara P
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1104-11. PubMed ID: 16988056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of irritable bowel syndrome: the mast cell connection.
    Santos J; Guilarte M; Alonso C; Malagelada JR
    Scand J Gastroenterol; 2005 Feb; 40(2):129-40. PubMed ID: 15764142
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of mast cells in bacterial enteritis.
    Sherman MA
    Am J Pathol; 2007 Aug; 171(2):399-401. PubMed ID: 17569775
    [No Abstract]   [Full Text] [Related]  

  • 8. Visceral sensation and irritable bowel syndrome; with special reference to comparison with functional abdominal pain syndrome.
    Nozu T; Okumura T
    J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():122-7. PubMed ID: 21443724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mucosal mast cell and IgA plasma cell responses to primary Trichinelia spiralis infection in BALB/c mice treated with ketotifen.
    Doligalska M; Laskowska M
    Wiad Parazytol; 2001; 47(4):597-601. PubMed ID: 16886396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome.
    Jovani M; Fiorino G; Danese S
    Aliment Pharmacol Ther; 2013 Jan; 37(2):277-8. PubMed ID: 23252779
    [No Abstract]   [Full Text] [Related]  

  • 11. The pathophysiology of irritable bowel syndrome.
    Schwetz I; Bradesi S; Mayer EA
    Minerva Med; 2004 Oct; 95(5):419-26. PubMed ID: 15467517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen.
    Schoch C
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):75-81. PubMed ID: 12648306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome - author's reply.
    Matricon J
    Aliment Pharmacol Ther; 2013 Jan; 37(2):278-9. PubMed ID: 23252780
    [No Abstract]   [Full Text] [Related]  

  • 14. [Dynamics of indices of visceral sensitivity in patients with irritable bowel syndrome treated with spasmolytics].
    Makarchuk PA
    Eksp Klin Gastroenterol; 2007; (6):126-9. PubMed ID: 18418922
    [No Abstract]   [Full Text] [Related]  

  • 15. Mast cell infiltration and degranulation in colonic mucosa in the irritable bowel syndrome.
    Talley NJ; Butterfield JH
    Am J Gastroenterol; 1996 Aug; 91(8):1675-6. PubMed ID: 8759703
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of Mast Cell Degranulation Relieves Visceral Hypersensitivity Induced by Pancreatic Carcinoma in Mice.
    Yu D; Zhu J; Zhu M; Wei K; Chen Q; Wu X; Miao X; Lu Z
    J Mol Neurosci; 2019 Oct; 69(2):235-245. PubMed ID: 31201657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell degranulation in rat mesenteric venule: effects of L-NAME, methylene blue and ketotifen.
    Kimura M; Mitani H; Bandoh T; Totsuka T; Hayashi S
    Pharmacol Res; 1999 May; 39(5):397-402. PubMed ID: 10328998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.
    Tuteja AK; Fang JC; Al-Suqi M; Stoddard GJ; Hale DC
    Scand J Gastroenterol; 2012 Oct; 47(10):1159-64. PubMed ID: 22783919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketotifen induced inhibition of histamine release in a non-IgE model of middle ear effusion.
    Berger G; Berger R; Goldberg A
    Pediatr Allergy Immunol; 2006 Feb; 17(1):43-8. PubMed ID: 16426254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms.
    Elsenbruch S
    Brain Behav Immun; 2011 Mar; 25(3):386-94. PubMed ID: 21094682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.